The Expression Of Thrombospondin-1 And P53 In CCRCC: Its Relationship To Angiogenesis, Cell Proliferation, And Cancer Specific Survival
UroToday.com - Clear cell renal cell carcinoma (CCRCC) is the most prevalent of the subtypes of renal cell carcinoma (RCC). Its prognosis is unpredictable because even small tumors may progress and end in metastatic disease and death. There is an urgent need for new molecular prognostic markers and new treatment targets. CCRCC is frequently associated with mutations in the von Hippel-Lindau tumor suppressor gene bringing about an increased VEGF expression and neovascularization. The putative role of trombospondin-1 (TSP-1) which is one of the most potent endogenous inhibitors of angiogenesis in the tumor-associated stroma is largely ignored in CCRCC.
The Relationship Between Age At Time Of Surgery And Risk Of Biochemical Failure After Radical Prostatectomy
UroToday.com - In the online edition of the British Journal of Urology International, a group from Columbia University Department of Urology report that older men undergoing radical prostatectomy (RP) for prostate cancer (CaP) do not have an increased risk of disease recurrence in the multivariate context that includes PSA level, Gleason score and clinical stage. The study is a single institutional retrospective study of 1, 983 men who underwent RP between 1988 and 2008. Men ages 40-64 formed one group, based upon preliminary assessment that biochemical failure among these men when further sub-stratified was not different. This group was compared to an older group of men age 65 and above.
The Importance Of Serum Prostate-Specific Antigen Testing Frequency In Assessing Biochemical And Clinical Failure After Prostate Cancer Treatment
UroToday.com - A research group under Dr. Eric Klein at the Cleveland Clinic evaluated how the frequency of PSA testing influences the determination that biochemical failure (bF) has occurred. In turn, those without a bF are less likely to undergo testing, such as a bone scan to find clinical failure (cF). The findings by Dr. Jay Ciezki and colleagues appear in the online version of Urology. The report is a retrospective study of 5, 616 patients who underwent radical prostatectomy, radiotherapy or brachytherapy between 1996 and 2007. bF for radical prostatectomy was defined as a PSA >0.4ng/ml and for radiotherapy the PSA nadir + 2 definition was used.
Challenging prevailing wisdom that only children with end-stage kidney disease suffer physical, social, emotional and educational setbacks from their disease, research led by Johns Hopkins Children's Center shows that even mild to moderate kidney disease may seriously diminish a child's quality of life. The findings, reported in the February issue of Pediatrics, suggest that earlier attention to quality-of-life issues in children with chronic kidney disease is needed. "Even mild and moderate declines in kidney function may lead to serious physical, emotional, intellectual and social challenges, " says lead investigator Arlene Gerson, Ph.
Repros Therapeutics Inc. (NasdaqCM:RPRX) announced that the Company and its consultants participated in a teleconference with the Division of Reproductive and Urologic Products of the FDA on January 25, 2010. The primary purpose of the meeting was to gain a better understanding of the FDA's position regarding the use of Repros' oral Androxal® product in the treatment of men with secondary hypogonadism wishing to preserve their fertility. The Company's data supports the notion that the negative feedback of exogenous testosterone administered by any route suppresses the hypothalamic-pituitary axis and hence spermatogenesis. The discussion with the FDA focused on two issues.
Measuring certain types of immune cells may predict the high risk of skin cancer after kidney transplantation, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). "There are differences in the immune system, and some of these are associated with the development of skin cancer after transplantation, " comments Robert Carroll, MD (The Queen Elizabeth Hospital, Woodville, South Australia). The researchers measured levels of key immune cells in 116 kidney transplant recipients, 65 of whom developed squamous cell skin cancers. "We were hoping to see if there were differences in the immune systems of patients who developed skin cancer after transplantation compared to those who did not develop skin cancer, " says Carroll.